Kevin Tang purchased 145,880 shares at $2.48, marking the largest insider purchase in the company's history. This significant accumulation by a major shareholder suggests confidence in the stock's recovery potential following a 28% pullback from its 52-week high.
Price context
The stock is currently trading at $1.11, sitting 28.39% below its 52-week high of $1.55 but 15.48% above its 52-week low of $0.9612. Despite a 9.9% gain over the past year, the shares are currently flat over the last 30 days.
Catalysts to watch
The merger with Serapha Bio is scheduled to close in the fourth quarter of 2026, which has driven a 90% rally in company history according to recent reports. Additionally, the stock was upgraded to a Zacks Rank #2 (Buy) on February 13, 2026, reflecting growing optimism about earnings prospects.
Risks
The company is currently unprofitable with a forward P/E of -1.72, and Simply Wall St. has highlighted concerns regarding the cash burn rate as a key risk factor for the business.
AI-generated context from public data. Not investment advice. Verify before trading.